

Human Journals **Research Article** November 2017 Vol.:8, Issue:1 © All rights are reserved by Bassem Abou Merhi et al.

Epidemiological Study of MDR-TB in Lebanon from 2005 to 2014



Accepted: Published: 2 November 2017 30 November 2017





www.ijsrm.humanjournals.com

Keywords: TB: Tuberculosis; MDR-TB: Multidrug-Resistant Tuberculosis; HBC: High Burden Countries; DOT; Directly Observed Therapy.

ABSTRACT

Tuberculosis (TB), a common infectious disease, is a major public health problem especially with increased resistance to conventional treatment. Multidrug-Resistant Tuberculosis (MDR-TB) is difficult to cure, needs prolonged and expensive treatment, and has high morbidity and mortality rates. To determine the epidemiological status of MDR-TB in Lebanon, the data of all MDR-TB patients in Lebanon from 2005 to 2014 has been collected in a retrospective descriptive study at Azounieh sanatorium and Quarantine TB center and analyzed. The results focused on the incidence, the resistance pattern, the treatment and its outcome. The study showed 56 cases notified in Lebanon since 2005, about 1/3 were foreigners, increasing in incidence in the last 3 years, with male and young age predominance, highest numbers in Mount Lebanon. One-third of patients had the primary disease, most of them concentrated between 2013 and 2014. During the study period, no drug susceptibility tests (DST) for second-line drugs exist existed in Lebanon, so XDR TB cases were difficult to diagnose. Lebanon is classified as a low burden country for MDR-TB but the incidence is increasing lately mainly among foreign workers.

INTRODUCTION:

At no time in recent history, has TB been a great concern as it is today? The infectious microorganism, Mycobacterium tuberculosis, which is spread almost exclusively by airborne transmission, causes TB. The disease mostly affects the lungs but also involve any site in the body. When patients with pulmonary TB cough, they produce tiny droplet nuclei that contain the bacteria, which can be transmitted to others. A person, who becomes infected with TB, remains infected for years. A healthy immune system does not become ill but is usually not able to eliminate the infection without medications. This condition is referred to as "Latent Tuberculosis infection." Patients with the latter infection are asymptomatic and cannot spread the disease. About 10% of non- Human Immunodeficiency Virus (HIV) associated- Latent Tuberculosis infection will become ill with active TB at some time during their lives. Treatment of active TB involves taking multiple anti-TB drugs for at least 6 months.

If the patient does not take the medications regularly and for the full treatment period, the disease may not be cured and may recur with resistance. This, lead us to the recent outbreaks of MDR-TB posing an urgent public health problem. Resistance can be acquired through different molecular mechanisms and can be primary or secondary to a previous anti-TB treatment. Essentially, drug resistance arises in areas with weak TB control programs, areas classified by World Health Organization (WHO) as "High Burden Countries" (HBC) for MDR-TB. There are 27 HBC for MDR-TB. In these countries, at least 4,000 cases of MDR-TB are diagnosed each year, and/or at least 10% of newly registered TB cases are of MDR-TB (1). Directly Observed Therapy (DOT) is the best way of ensuring patient control. Another major control intervention is to detect and preventively treat persons who have latent tuberculosis infection that may be at high risk of developing the active form [2]. MDR-TB diagnosis and treatment are complicated but are improving nowadays through the innovational techniques, the newest drugs and the WHO and political efforts. The treatment is highly expensive, requires patients adherence, with common side effects. Lebanon is at risk for increasing MDR TB mainly due to its geographic location and the frequent immigrations from different endemic areas recently. Only two epidemiological studies were done on MDR-TB patients in Lebanon, but no publications in the last 10 years. This study cover MDR TB cases treated since the introduction of 2nd line TB drugs in Lebanon in 2005 and will describe the epidemiology and outcome of treatment.

TB control in Lebanon: In 1906, was the first Lebanese society for anti-TB. On 1908, first sanatorium, Maameltine, transferred after to Hemline. On 1914 second sanatorium appeared, Bhanness. On 1918 third sanatorium developed, Dahr el Bachek. On 1923 fourth sanatorium issued, Maameltine, the Armenian sanatorium which later on transferred on 1938 to Azounieh MDR-TB sanatorium. On 1950 first anti-TB center in Lebanon was opened, Quarantine. There are 8 TB public control centers, 2 at the central level in Beirut, 6 at the provincial level. The private sector refers 80% of total TB cases of the national TB programs. TB and DOTS strategy: First launch of DOTS was in 1998 with the help and collaboration of WHO, GLC, and IDA. On 2005 second, line drugs became available in Lebanon.


National Epidemiology: Two recent national studies: The first study: 84 samples of new pulmonary TB cases with three samples of patients previously diagnosed and under treatment, were collected between April 2004 and October 2005 from all Lebanese provinces. Resistance pattern: The isolates included 21 resistant cases (24.1%) (18 primary + 3 previously treated) in Beirut 15% (3/20) versus outside Beirut 27% (18/67) (OR= 0.48, 95% CI: 0.126–1.82, P = 0.085). They found single-resistant 4.6%; double-resistant 12.6%; tripleresistant 4.6%; quadruple-resistant 2.3%. Three of the MDR cases were the previously treated patients (3.5%) [3], the resistance pattern was: R 42.9% - H 81.0% - E 19.1% - S 76.2%. All MDR cases, except for one, were males, resulting in an M: F ratio of 7.0 (7/1) (OR = 3.1, 95% CI: 1.27–7.39, P= 0.3). All cases of MDR were concentrated within patient's aged 40– 69 years. 75% > 50 years. (Versus TB patients: 72% < 50 years and 7% are aged 20 or less). Most forms of resistance to drugs (79%) involved Isoniazid and Streptomycin, 17 resistance patterns were observed more than once. 9/17 came from the same regions [4]. The second study: Published in 2006, is conducted by Dr. M. Saade between July 2002 and April 2004, comparing the Prevalence of primary versus secondary MDR-TB in Lebanon. The study, which included 190 newly diagnosed tuberculosis patients, had found that 1% had the primary MDR-TB infection (0.66% Lebanese vs. 2.5% non-Lebanese). DST did on another 21 previously treated TB patients showed: 5 cases with no growth, 4 cases sensitive to all 1st line Anti-TB drugs (3 Lebanese versus 1 non-Lebanese), 1 patient mono-resistant to Isoniazid and 11 patients MDR (6 Lebanese versus 5 non-Lebanese) [5]. Concerning the MDR-TB notifications by WHO (Table 1) [6].

	YEAR	TOTAL CONFIRMED CASES ^a OF RR-/MDR-TB	TOTAL CONFIRMED CASES ^a OF MDR-TB	ESTIMATE OF MDR-TI NOTII	BAMONG
Lebanon	2005	3	3		
	2006	4	4		
	2007	2	2		
	2008	3	3		
	2009	5	4		
	2010	7	7		
	2011	3	3		
	2012	7	6		
	2013	10	9	7	(0-13)

Table 1: MDR-TB notifications by WHO in Lebanon 2005-2013

Treatment costs in Lebanon: 100\$ per sensitive TB patient and 2500-4000\$ per MDR TB patient.

Objectives:



MATERIALS AND METHODS:

Study subjects: A questionnaire completed by our team allowing collection of all MDR-TB patients data in Lebanon between January 1, 2005 and December 31, 2014. Information included demographic data, comorbidities, TB classification and resistance pattern, treatment,

adverse effects, microbiological and treatment outcome. Patient's names remained anonymous.

Exclusion Criteria's:

Patients diagnosed with MDR-TB but with no documented DST result. Patients who didn't receive treatment were included in the general incidence of the disease but were excluded from the further statistical analysis.

Inclusion Criteria's:

Patients had documented MDR TB infection, which had received or still on anti-tuberculosis therapy, in Lebanon between 2005 and 2014.

Methods:

Patient's data was gathered from Quarantine TB center and Azounieh sanatorium using a questionnaire (Appendix 1). Patients contacts (example: phone numbers) were available in case of lacking information.

Appendix 1: Questionnaire Form



Item 1) Patient's In	itials:	
Item 2) Gender:	Female	Male
Item 3) Date of Birt	th:	
Item 4) Social Histo	ory:	
Nationality:		Resi
Item 5) Patient's W	eight:	
Item 6) TB classific	cation:	
Pulmonary	Extra-pulmonary	
Item 7) HIV status	Positive	Negativ

Item 8) Registration group:

New	Previously	treated	Failure					
Item 9) Risk Factors:								
Diabetes	Renal disease	Drugs	Hematologic ne	eoplasm				
Head and ne	eck cancer	steroids >1m	Transplant	Cirrhosis	Gastric			
surgery	Celiac disease	others						
Item 10) Da	te of sample ta	ken for DST: -						
Item 11) Res	sult of DST: R	versus S H	R	S	E FQ			
Item 12) Da	te of initial trea	tment:						
Item 13) Da	Item 13) Date of initiation of second line regimen treatment							
Item 14) Sec	cond line TB di	rugs received -						
Item 15) Outcome of treatment:								
Cure Left the cou	Death ntry	Complete	HUMATIN ON T	reatment	lost to follow	up		
If death, causes: TB non TB								
Item 16) Side effects experienced during treatment: Yes No								
If yes specify:								
- Arthralgia								
- Myalgia								
- Headache								
-Gastrointestinal (Nausea, Anorexia, Diarrhea, Vomiting, Abdominal pain,								
Epigastric pain)								
- Neuropathy								
Citation: Bassem Abou Merhi et al. Ijsrm.Human, 2017; Vol. 8 (1): 172-188.								

Exclusion	Year	Gender	Registration Group	Nationality	DST	Outcome	Causes of Exclusion
Case 1	2013	Female	Pulmonary	Ethiopian	Sensitive to E Only	Left the Country	No Treatment
Case 2	2010	Female	Pulmonary	Lebanese	Sensitive to S Only	Loss of Follow up	No Treatment
Case 3	2008	Female	Lymphadenitis	Palestinian	No DST	Left the Country	No DST
Case 4	2007	Female	Pulmonary	Russian	Resistant to All	Left the Country	No Treatment
Case 5	2006	Female	Pulmonary	Syrian	Resistant to All	Left the Country	No Treatment

- Liver failure

- Hearing problem

- Psychiatric

- Severe allergy

Item 17) Month of conversion of smear and culture ------

Item 18) Results: + or -

Month 0: smear culture GeneXpert

Month 1: smear culture GeneXpert

Month 2:

Data was uploaded to Excel sheet and statistical analysis was done by SPSS v16.

RESULTS:

Between 2005 and 2014, 56 patients had the MDR-TB infection based on Azounieh sanatorium and Quarantine TB center Data. Five out of these 56 patients were excluded from the study but were included in the general incidence number (Table 2).

General Epidemiology:

While the Lebanese population has changed in size from 3.8 to 4.1 million in the previous years and up to 5.8 million in 2014 [43], data showed that sensitive TB population has

increase in number from 391 cases in 2005 to 499 in 2011 then up to 730 cases in 2014 (despite a previous continuous decrease between 1999 and 2005), whereas the distribution of MDR-TB cases over years showed the highest numbers in the last 3 years (2012, 2013, 2014 respectively) accounting alone for 22 cases (43%) (Figures 1, 2), MDR-TB to sensitive-TB ratio throughout the last decade were the highest in 2005 2%, and the lowest in 2008 0.3% with a mean ratio of 0.95%. Concerning the nationality, 36 were Lebanese vs. 15(29.41%) foreigners: 5 Palestinians, 5 Syrians, 3 from Ethiopia, 1 from Angola and 1 from Russia. 9/15 (60%) of the foreigners and all 5 Syrian MDR-TB patients were diagnosed between 2012 and 2014.




Figure 1: TB Cases in Lebanon 2005-2014




Figure 2: MDR-TB Cases in Lebanon 2005-2014

Mean age was 40 (16-70) distributed among males 45 and females 32, mean age in Beirut 37.5 (23-61), outside Beirut 41 (16-70). In addition, we had only one pediatric patient: 16-year-old Syrian female. About 2/3 (62.8%) of patients were males, with M: F in Beirut 2.3/1 and outside Beirut 1.6/1. Mean weight was 62 kg (36-97) distributed among males 64 kg and

females 58 kg (figure 3). Mount Lebanon alone, accounts for 41% of cases, another 18% live in Beirut. (Refer Figure 4). All patients coming from South Lebanon were living in Tyre.




Figure 3: Distribution of Patients Based on Gender, Nationality, and Age.




Figure 4: Geographic Distribution of MDR-TB in Lebanon 2005-2014

Documented risk factors included 8 DM II, 1chronic bronchitis, one chronic kidney disease, one patient was HIV+ with CD4 75 and Viral load 1.4 million at diagnosis, one patient had recurrent knee trauma and operations with subsequent osseous MDR-TB, and 76% were completely healthy.

MDR-TB Classification and resistance pattern:

Concerning the disease itself, we had 48 pulmonary cases versus three extra pulmonary (Divided into two Lymphadenitis and one osseous). 32 patients had secondary MDR-TB, 17(one third) had primary MDR-TB and two patients had MDR-TB with the failure of the treatment and readmission for retreatment. Percentages of primary and secondary MDR-TB came very similarly in both Lebanese and non-Lebanese patients. Primary resistance was highly dominant in both Lebanese and non-Lebanese patients in 2013 and 2014 and absent between 2005 and 2008. Patients were divided also based on the number and type of drugs to which the isolates were resistant: 26 (51%) had resistance to 4 drugs or more (44.4% in Lebanese vs. 66.7% in foreigners), 17 had resistance to three drugs and eight had resistance to only two drugs. No XDR-TB patients. The highest percentages of resistance were to Isoniazid and Rifampin, 100% and 94% respectively, and we had about 70% resistance for both Streptomycin and Ethambutol. Only one isolate was resistant to FQ.

Treatment:

Treatment was standardized including first-line drugs plus kanamycin, Ethionamide, Cycloserine and Levofloxacin with the introduction of Capreomycin since 2014. Of these patients, 41/51 (80.4%) had conversion, 36/41 (87.8%) had 2 consecutive negative smears or cultures in the first 6 months of treatment, with early conversions at first month: 8/41 (19.5%) and at second month: 25/41 (61%) and very minimal difference between Lebanese and non-Lebanese population. Common side effects of the treatment were GI symptoms (abdominal pain, nausea, vomiting, and diarrhea), myalgia, arthralgia and peripheral neuropathy, 3 patients had a severe headache, 3 patients had some hearing loss (1 died, 1 was lost to follow up (F/U), 1 cured), 1 patient had liver failure (died), 1 person had severe allergy to Rifampicin and another 1 had personality changes with new psychotic features (lost to follow up). Of the 51 treated patients, 26 (51%) had complete cure (55.6% Lebanese versus 40% foreigners), 5 completed the treatment without cure, 10 still on treatment for the time, 7 was lost to F/U (1/7 had left the country), 3 patients died (5.9%). Then Success rate (cure + complete) was 60% (70% in Lebanese versus 40% in foreigners) and 10 patients had the failure of treatment which represent 20% of the treated patients (11% in Lebanese vs. 40% in foreigners) (table 6).

Values	Final Out Come rouping	Nationality	Group	
		Foreign	Lebanese	Total
Number of Patients	Failure	6 (40%)	4 (11.11%)	10 (19.61%)
	Still On Treatment	3 (20%)	7(19.44%)	10(19.61%)
	Success Rate	6 (40%)	25(69.44%)	31(60.78%)
Total Number Of Patients		15	36	51

Table 6: outcome of treatment in Lebanese and non-Lebanese patients

Death causes severity of disease (after 9 months of treatment), myocardial infarction (within the first month of treatment), and liver failure (after 6 months of treatment). The success rate was 100% in 2006, 2007 and 2009. Lebanese patients had the highest cure rate in the first 5 years of the study (Figure 7).




Figure 7: Outcome of Treatment in Different years: Lebanese Versus non-Lebanese

The Cure rate based on the number of drugs to which the isolate is resistant showed: 62.5% with 2 drugs, 76.5% with 3 drugs and 30.7% in 4 drugs and more. All 3-death cases happened when a patient had resistance to 4 drugs (Figure 8).




Figure 8: Outcome of Treatment Based on Resistance Pattern

When evaluating the outcome of treatment with patient's comorbidities prior to the disease, we found that 22/26 cured patients were previously healthy, the other 4/26 had diabetes II, 7 patients were lost to follow up: 4 healthy, 1 had HIV, 1 had chronic kidney disease and 1 patient DM II, 3 died: 1 had chronic bronchitis and another 1 had DM II.

And when comparing the outcome of treatment with the month of conversion after receiving the second line drugs, we noticed that all patients who died had no conversion, 2/10 of patients, who still on treatment for the time, had no conversion and the other 8/10, converted their smears/cultures within the first 6 months, 2/7 of patients had no conversion at time they were lost to follow up.

DISCUSSION

TB incidence in Lebanon has declined between 1999 and 2005 but started to increase in the last decade with the highest numbers in the last 3 years. MDR-TB in Lebanon, 56 patients was diagnosed between 2005 and 2014. The number of MDR-TB patients varies yearly but the last 3 years between 2012 and 2014 accounts alone for 41% of cases. About 30% of MDR-TB patients are foreigners, 60% of this non-Lebanese population were diagnosed in the last 3 years only. In a mean average less than 1% of TB cases are MDR-TB. These findings could be explained by the recent demographic changes in Lebanon and the surrounding, especially after the arrival of more than million refugees from civil Syrian war. It could be also due to the higher consciousness and the awareness programs since the arrival of the refugees. Another possible explanation is the improvement of diagnostic methods recently for example with the usage of GeneXpert in Lebanon since 2014. Finally the increasing needs for

foreigners employees (Examples: housekeeper, babysitter...) has led to increasing immigration from HBC (Ethiopia, Philippines, India, Pakistan...). In Lebanon most of MDR-TB Foreigners came from 2 HBC: Ethiopia and Russia and 2 surrounding countries in low socioeconomic conditions and war: Syria and Palestine. Patients are young, the mean age was about 40 (16-70), very similar to the latest national studies and data in other developing countries, reflecting primary transmission. We have only one pediatric case. M: F is two (7 in 2005), compatible male dominance with the literature and may be due to more frequent TB exposure in men. Mean weight was 59.2 kg (Low BMI is a risk factor in all types of TB infection). Concerning the geographic distribution, more than 40% of cases came from Mount Lebanon, with 18% in Beirut came second, compared with 33% in Mount Lebanon and 23% in Beirut in the latest national study. To Note all patients from the south live in Tyre possibly due to the contact of Tyre population with TB patients treated at Tyre sanatorium. Risk factors included DM II, chronic bronchitis, CKD and HIV. Most of patients were healthy, looking to the young population infected with the disease. We have only 1 MDR-TB HIV (+) patient in Lebanon in the last decade. We have 3 extrapulmonary cases: of which 2 lymphadenitis (which is the most common site of extrapulmonary TB) and 1 osseous (which occurred in the patient with recurrent knee infections and operations). About half of patients had resistance to 4 drugs or more (44.4% in Lebanese vs. 66.7% in foreigners), only 1 isolate was resistant to FQ. No XDR-TB in Lebanon since no DST for second line therapy until now. The highest resistance observed was to Isoniazid and Rifampin, whereas in 2005 the most common resistance isolates were for Isoniazid and Streptomycin. About 2/3 of cases are secondary MDR-TB and 1/3 are primary MDR-TB. These numbers are very similar in Lebanese and non-Lebanese population. Primary resistance was very high in the last 2 years (78.5% versus 33% in the 10 years). Secondary infection is caused by inappropriate treatment of sensitive TB cases and then a need for more organized DOT. Increasing primary infections is likely due to recent foreigner's immigration. Success rate in sensitive TB patients was alarming in 2014 and has declined, as low as 70% (93% Lebanese versus <50% Foreigners (because of lost to follow up)) to be compared with > 80% in the previous years and 86% worldwide. In MDR-TB, about half of patients, 51%, had complete cure (55.6% Lebanese vs. 40% foreigners), Success rate was 60% (70% Lebanese vs. 40% foreigners), to be compared with the average worldwide success rate of 48% in 2011. These success rate numbers are underestimated and can be as high as 75% (86% Lebanese Vs. 50% foreigners), if we exclude in the outcomes those 10 patients who still on treatment for the time and may become cured specially that 80% of them had converted their smears/cultures within the first 6 months of

treatment. The lowest cure rate happened with 4 drugs and more about 30% compared with 62.5% and 76.5% in isolates resistant to 2 and 3 drugs respectively, 5.9% of patients Died. Etiologies included: 1) Severity of disease (after 9 months of treatment) 2) Myocardial infarction (within the first month) and 3) Liver failure (after 6 months of treatment). All 3 death cases had no conversion and had resistance to at least 4 drugs. Failure of treatment was 20% (11% in Lebanese versus 40% in foreigners), 7 patients were lost to follow up after the intensive phase in sanatorium, which is very alarming and dangerous and lead to many questions concerning DOT's success in Lebanon. We may suspect better outcomes for the years 2013 and 2014 especially with the arrival of new 2nd line therapy drugs such as Capreomycin. Outcome of treatment is likely better with early conversion and less resistance. There were no big changes in the outcome of treatment with the different years. Common side effects of 2nd line drugs therapy included GI problems, arthralgia, Myalgia and peripheral neuropathy. Other severe symptoms: unbearable headache, hearing loss, liver failure, severe allergy and psychosis. In Lebanon, only patients who are suspected to have MDR-TB should be tested for sensitivity including: previously treated patients, all HIV (+) patients, contact with MDR-TB patients, TB not responding to first-line TB drugs within 2 months, disseminated TB as milliary and meningitis, patients coming from HBC, and patients (case by case) who were previously treated and lost to follow up. Also patients are not allowed to take flights before 15 days and 2 months of treatment for sensitive and resistant TB patients respectively. We were obliged to exclude 5 patients from the study because they had no documented data or files. This exclusion may interfere with the results, but 4 out of these 5 patients had left the country and are unreachable so we couldn't include them in our study. Weakness of the study include: Size of studied population, results are an underestimation of the reality of MDR-TB in Lebanon because of difficulties in screening and diagnosis, lack of 2nd line DST in a way XDR-TB diagnosis and individualized treatment regimen still impossible, patients who were lost to follow up and didn't complete their treatment. The results of this study represent the entire Lebanese population between 2005 and 2014 because the data of every patient diagnosed with MDR-TB in Lebanon was carefully collected; it gives us an idea of the epidemiology of MDR-TB in our country and is a sign of increasing need for awareness and public health reactions. The big debate of today concerning TB in Lebanon and worldwide is concerned about screening issues: which population should be screened for both sensitive and resistant TB? And about latent TB infection treatment: Treating those patients is it preventing active TB or increasing risks for MDR-TB.

CONCLUSION

MDR-TB is a new entity in Lebanon requiring awareness and attention. Lebanon is a country where the population is affected by thousands of immigration and emigrations yearly and is situated in the Middle East region under remarkable changes recently. Our study represents MDR-TB in all Lebanon in the last decade since the beginning of MDR-TB treatment; it included only 51 patients but could be a new beginning in the understanding of this disease and to turn on an alarming system. Improving both primary and secondary prevention in either sensitive or resistant TB patients, amelioration of patient's compliance to treatment, Sanatorium abilities and DOTs strategies, regular surveillance programs, serious intervention of the WHO and public health to control the disease and increasing awareness on this subject will be essential in the upcoming years to confine the problem and lead us to the hopes of disease's elimination.

REFERENCES

1. TB Statistics. Geneva: World Health Organization. [2013; 2015, Feb 5].

2. Management of persons exposed to multidrug-resistant tuberculosis [internet]. Atlanta: Centers for Disease Control. [1992, June 19; 2015, Feb 5]

3. DR-TB Drugs under the Microscope: Sources and Prices of Drug-Resistant Tuberculosis Medicines. Medecins Sans Frontiere (MSF) and the International Union against Tuberculosis and Lung Disease (The Union). [2011, Nov 16; 2014, Aug (4) Report of the meeting of the WHO Global Task Force on XDR-TB [internet]. Geneva: World Health Organization. [2006, Oct 9-10; 2015, Jan 18].

4. M. Hamze, A. Rahmo, M. Saade. Characterization of Mycobacterium tuberculosis of Lebanese patients by double-repetitive-element polymerase chain reaction. EMHJ, 2010; 16(8): 812-819. (4) Koehler, Christopher W. Consumption, the great killer. Modern Drug Discovery 5 2002; (5): 47–49.

5. Araj G, Saade H, Itani L. Nationwide study of drug resistance among acid-fast bacilli positive pulmonary tuberculosis cases in Lebanon. International Journal of Tuberculosis and Lung Disease, 2006, 10(1):63–67.

6. Global Tuberculosis Report 2014, Key indicators for the WHO Eastern Mediterranean Region. Geneva: World Health Organization. [Updated in 2015, Feb 18; 2015, Feb 25].

7. Drug-Resistant Tuberculosis: a Historical Overview. Boston: USAID. [2012, July 10; 2015, Feb 7].

8. World TB day. Boston: USAID. [2013, March 22; 2015, Feb 7].

9. ALEX SAKULA. Carlo Forlanini, inventor of artificial pneumothorax for treatment of pulmonary tuberculosis. Thorax 1983; 38: 326-332.

10. Baker MA, Lin HH, Chang HY, Murray MB. The risk of tuberculosis disease among persons with diabetes mellitus: a prospective cohort study. Clin Infect Dis 2012; 54:818-825.

11. Hussein MM, Mooij JM, Roujouleh H. Tuberculosis and chronic renal disease. Semin Dial 2003; 16:38-44.

12. Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006; 55:19-26.

13. Cain KP, Haley CA, and Armstrong LR, et al. Tuberculosis among foreign-born persons in the United States: achieving tuberculosis elimination. Am J Respir Crit Care Med 2007; 175:75-79.

14. Schluger NW, Rom WN. Current approaches to the diagnosis of active pulmonary tuberculosis. Am J Respir Crit Care Med 1994; 149:264-267.

15. Fitzwater SP, Caviedes L, Gilman RH, et al. Prolonged infectiousness of tuberculosis patients in a directly observed therapy short-course program with standardized therapy. Clin Infect Dis 2010; 51:371-8.

16. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363(11):1005-15.

17. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME. Rapid molecular screening for multidrugresistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med. 2008; 177:787–792.

18. Choi JH, Lee KW, Kang HR, Hwang YI, Jang S, Kim DG, et al. Clinical efficacy of direct DNA sequencing analysis on sputum specimens for early detection of drug-resistant Mycobacterium tuberculosis in a clinical setting. Chest. 2010;137:393–400

19. Gumbo T, Louie A, Liu W, et al. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J Infect Dis 2007; 195:194.

20. Middle brook G. Isoniazid-resistance and catalase activity of tubercle bacilli; a preliminary report. Am Rev Tuberc 1954; 69:471

21. Donnabella V, Martiniuk F, Kinney D, et al. Isolation of the gene for the beta subunit of RNA polymerase from rifampicin-resistant Mycobacterium tuberculosis and identification of new mutations. Am J Respir Cell Mol Biol 1994; 11:639.

22. Scorpio A, Lindholm-Levy P, Heifets L, Gilman R, Siddiqi S, Cynamon M et al. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1997; 41:540-3.

23. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998; 79:3.

24. Nair J, Rouse DA, Bai GH, Morris SL. The rpsL gene and streptomycin resistance in single and multiple drug-resistant strains of Mycobacterium tuberculosis. Mol Microbiol 1993; 10: 521-527

25. Cambau E, Sougakoff W, Jarlier V. Amplification and nucleotide sequence of the quinolone resistancedetermining region in the gyrA gene of mycobacteria. FEMS Microbiol Lett 1994; 116:49-56

26. Banerjee A, Dubnau E, Quemard A, et al. inhA, a gene encoding a target for Isoniazid and Ethionamide in Mycobacterium tuberculosis. Science 1994; 263:227-230

27. D. Falzon, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J September 2011 38:516-528

28. Ziganshina LE1, Vizel AA, Squire SB. Fluoroquinolones for treating tuberculosis. Cochrane Database Syst Rev. 2005 Jul 20;(3)

29. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva, World Health Organization, 2007

30. Caminero JA, World Health Organization, American Thoracic Society, British Thoracic Society. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis 2006; 10: 829-37.

31. The WHO / IUATLD global project on anti-tuberculosis drug resistance surveillance: Anti-tuberculosis drug resistance in the world, report No 4. Geneva. World Health Organization 2008; 394: 1–120.

32. Caminero JA1, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis. 2010 Sep;10(9):621-9

33. Ershova JV, Kurbatova EV, Moonan PK, Cegielski JP. Acquired resistance to second-line drugs among persons with tuberculosis in the United States. Clin Infect Dis 2012; 55:1600-1607.

34. David HL, Laszlo A, Rastogi N. Mode of action of antimycobacterial drugs. Acta Leprol 1989; 7 Suppl 1:189-94.

35. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012; 366(23):2151-60.

36. Sung SW, Kang CH, Kim YT, et al. Surgery increased the chance of cure in multi-drug resistant pulmonary tuberculosis. Eur J Cardiothorac Surg 1999; 16:187-93.

37. Somocurcio J G, Sotomayor A, and Shin S. et al Surgery for patients with drug-resistant tuberculosis: report of 124 cases receiving community-based treatment in Lima, Peru. Thorax 2007. 62416–421.421

38. Global tuberculosis report 2014. Geneva: World Health Organization. [Updated 2015, Feb 18; 2015, Feb 22].

39. WHO. Anti-tuberculosis drug resistance in the world, the fourth global report by the WHO/IUATLD Global project on anti-tuberculosis drug resistance surveillance. Geneva: World Health Organization. [2008b; 2014, Nov 25].

40. Global Tuberculosis Control 2013. Geneva: World Health Organization. [2013; 2015, Jan 23].

41. The Global Plan to Stop TB 2011-2015. Geneva: World Health Organization. [2011; 2015, Jan 1].

